Gen XY Updates from GlobeNewswire
2026-02-07T01:25:13Z
MEXICO CITY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO) (“Aeroméxico”) will hold a live conference call and webcast on Tuesday, February...
2026-02-07T00:54:16Z
A Closer Look at Everygame’s Super Bowl LX Betting Bonus, Eligibility, and Key Terms
2026-02-07T00:36:40Z
A look at Bovada’s current new-user bonus structure, Super Bowl betting markets, and platform features drawing attention ahead of the game
2026-02-07T00:08:16Z
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb reviews often evaluate when comparing products in the male enhancement supplement category
2026-02-07T00:00:00Z
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
2026-02-06T22:40:19Z
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching eye health supplement options, sublingual liquid supplement formats, and ingredient transparency in the...
2026-02-06T22:17:00Z
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of...
2026-02-06T21:56:28Z
A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product details, refund policies, and what consumers commonly research before purchasing an at-home teeth whitening kit
2026-02-06T21:30:00Z
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of...
2026-02-06T21:30:00Z
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically...
2026-02-06T21:05:00Z
BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee)...
2026-02-06T21:01:00Z
NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin...
2026-02-06T21:01:00Z
BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted...
2026-02-06T21:01:00Z
WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the...
2026-02-06T20:54:42Z
New exchange connection brings first player-specific sports event contracts to DraftKings Predictions
2026-02-06T18:06:00Z
Celebrate the Holiday Season with Tradition and Cheer on December 5, 2026, in Mooresville, IN
2026-02-06T17:00:00Z
East Hanover, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery...
2026-02-06T17:00:00Z
Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery capabilities...
2026-02-06T16:00:00Z
CHICAGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced that Andy Brailo has joined the Company as Chief Commercial Officer....
2026-02-06T14:46:25Z
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025
2026-02-06T14:25:00Z
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer...
2026-02-06T14:15:00Z
NORTH PALM BEACH, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with...
2026-02-06T14:00:00Z
ORLANDO, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Westgate Foundation, the philanthropic arm of Westgate Resorts, announced today that it has awarded $845,000 in grants to support 64 community-focused nonprofit...
2026-02-06T13:55:00Z
Live video webcast on Wednesday, February 11th at 1:40 PM EST
2026-02-06T13:36:24Z
New York City, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Tired of no deposit bonus casinos burdening you with high wagering rules, tiny cashout caps on free spin wins, or...
2026-02-06T13:30:00Z
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis...
2026-02-06T13:00:00Z
A New Winter Report Published By Towards Healthcare Points to a “Rising Lifestyle of Beauty Awareness”
2026-02-06T13:00:00Z
The Detox-Focused, Buddhist-Inspired Nutraceutical Brand’s Brick-and-Mortar Presence in the Golden State Is Quickly Growing
2026-02-06T13:00:00Z
DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for...
2026-02-06T13:00:00Z
SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it...
2026-02-06T13:00:00Z
CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
2026-02-06T12:55:00Z
Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind’s lead MEAI candidate for addiction-related and other CNS disorders
2026-02-06T12:55:00Z
Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI
2026-02-06T12:30:00Z
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on...
2026-02-06T12:30:00Z
A new heart pizza available February 9–15
2026-02-06T12:30:00Z
SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
2026-02-06T12:30:00Z
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment...
2026-02-06T12:05:00Z
~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~
2026-02-06T12:00:00Z
WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today...
2026-02-06T12:00:00Z
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results...
2026-02-06T12:00:00Z
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a highly...
2026-02-06T12:00:00Z
BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported...
2026-02-06T08:30:00Z
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year...
2026-02-06T07:30:00Z
VALNEVA
2026-02-06T06:30:37Z
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025
2026-02-06T06:00:00Z
Allschwil, Switzerland – February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker and...
2026-02-06T05:32:48Z
New York, US, Feb. 06, 2026 (GLOBE NEWSWIRE) -- After years of player complaints about delayed withdrawals and surprise fees, Lucky Rebel is emerging as one of the highest paying online...
2026-02-06T05:00:00Z
ZURICH, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Chiral, a Swiss nanotechnology company pioneering next-generation semiconductor and quantum technologies with nanomaterials, today announced the successful closing of a $12 million seed...
2026-02-06T01:51:30Z
An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth eligibility considerations, and regulatory factors consumers are researching before...
2026-02-06T00:53:09Z
An informational overview examining compounded semaglutide vs FDA-approved GLP-1 medications, telehealth platform evaluation criteria, and what consumers consider when researching prescription weight management treatment options following recent regulatory developments
